Update on Hepatitis C Treatment

, Clinical Instructor, UCLA School of Medicine, Los Angeles, California, and , Medical Director, Liver Transplantation, Cedars-Sinai Medical Center, Associate Professor of Medicine, UCLA School of Medicine, Los Angeles, California


February 15, 2001

In This Article

Consensus Interferon

Consensus IFN (CIFN; IFN alfacon-1, Amgen, Thousand Oaks, California) is a genetically engineered compound synthesized by combining the most common amino acid sequences from naturally occurring IFNs.[19,20] CIFN shares 88% homology with IFN-alfa and 30% with IFN-beta. Although it has greater cytokine induction, antiviral, antiproliferative, natural killer cell, and gene-induction activities than both IFN-alfa 2a and IFN-alfa 2b on an equal mass basis, initial studies with the recommended CIFN dose of 9 mcg in IFN-naive patients with chronic hepatitis C resulted in viral response rates similar to those achieved with standard IFN-alfa monotherapy.[19,20]

More recently, higher-dosage CIFN regimens of 15 mcg thrice weekly were reported to result in virologic SRs of 13% in prior NRs and 58% in relapsers treated for 48 weeks.[21]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.